Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H16N2O2 |
| Molecular Weight | 256.2997 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC2=C(CC(CN3C=CN=C3)CC2)C=C1
InChI
InChIKey=VJJHOPPXRPHVCA-UHFFFAOYSA-N
InChI=1S/C15H16N2O2/c18-15(19)14-4-3-12-7-11(1-2-13(12)8-14)9-17-6-5-16-10-17/h3-6,8,10-11H,1-2,7,9H2,(H,18,19)
Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904) in man after repeated oral doses. | 1990 Jul |
|
| Inhibitory effect of thromboxane A2 synthetase inhibitor, DP-1904, on antigen-induced contraction of human lung parenchyma. | 1996 Dec |
|
| A possible involvement of thromboxane A2 and peptide leukotrienes in hyperresponsiveness of Sephadex-treated rat lung parenchyma. | 1999 Jan |
Patents
Sample Use Guides
Japanese normal male volunteers received repeated oral doses of 200 mg every 12 h for 4 doses, or 400 mg every 24 h for 2 doses, or 200 mg every 12 h for 14 doses.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: An augmented contraction and elevated thromboxane (TX) B2 release were observed, when the isolated parenchyma from Sephadex-treated rats was stimulated by 5-hydroxytryptamine (5-HT).
In the Sephadex-induced hyperresponsiveness model, Nafagrel at the concentrations of 3 x 10(-7) to approximately 3 x 10(-6) M, reduced the augmented contraction.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Fri Dec 15 16:29:09 GMT 2023 , Edited by admin on Fri Dec 15 16:29:09 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
65851
Created by
admin on Fri Dec 15 16:29:09 GMT 2023 , Edited by admin on Fri Dec 15 16:29:09 GMT 2023
|
PRIMARY | |||
|
SUB09113MIG
Created by
admin on Fri Dec 15 16:29:09 GMT 2023 , Edited by admin on Fri Dec 15 16:29:09 GMT 2023
|
PRIMARY | |||
|
97901-21-8
Created by
admin on Fri Dec 15 16:29:09 GMT 2023 , Edited by admin on Fri Dec 15 16:29:09 GMT 2023
|
PRIMARY | |||
|
100000084429
Created by
admin on Fri Dec 15 16:29:09 GMT 2023 , Edited by admin on Fri Dec 15 16:29:09 GMT 2023
|
PRIMARY | |||
|
6700
Created by
admin on Fri Dec 15 16:29:09 GMT 2023 , Edited by admin on Fri Dec 15 16:29:09 GMT 2023
|
PRIMARY | |||
|
C056295
Created by
admin on Fri Dec 15 16:29:09 GMT 2023 , Edited by admin on Fri Dec 15 16:29:09 GMT 2023
|
PRIMARY | |||
|
C76398
Created by
admin on Fri Dec 15 16:29:09 GMT 2023 , Edited by admin on Fri Dec 15 16:29:09 GMT 2023
|
PRIMARY | |||
|
CHEMBL1189780
Created by
admin on Fri Dec 15 16:29:09 GMT 2023 , Edited by admin on Fri Dec 15 16:29:09 GMT 2023
|
PRIMARY | |||
|
98PDQ9OL4V
Created by
admin on Fri Dec 15 16:29:09 GMT 2023 , Edited by admin on Fri Dec 15 16:29:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
